Skip to content

Ubrogepant

Calcitonin Gene-related Peptide Receptor Antagonist — NERVOUS SYSTEM

Also known as: ubrelvy

OnpFDA approvedATC N02CD04

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Ubrogepant is an onp drug in the Calcitonin Gene-related Peptide Receptor Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Calcitonin Gene-related Peptide Receptor Antagonists. DrugCentral lists 1 molecular target, including CALCRL. Recorded indications include Migraine.

  • Approval status: onp (first approved 2019 by the FDA).
  • Drug class: Calcitonin Gene-related Peptide Receptor Antagonist.
  • Mechanism of action: Calcitonin Gene-related Peptide Receptor Antagonists.
  • Molecular targets: CALCRL (1 listed in DrugCentral).
  • Indications: Migraine.
  • ATC code: N02CD04 (Calcitonin gene-related peptide (CGRP) antagonists).
  • Molecular formula: C29H26F3N5O3; molecular weight 549.55 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Migraine

Mechanism & targets

Mechanism of action (MoA)Calcitonin Gene-related Peptide Receptor Antagonists
Established pharmacologic classCalcitonin Gene-related Peptide Receptor Antagonist

Molecular targets (1)

TargetGeneActionActivity
Calcitonin gene-related peptide type 1 receptorCALCRLantagonistKi 10.20

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2019-12-23FDA—ALLERGAN

ATC classification

ATC codeTherapeutic hierarchy
N02CD04NERVOUS SYSTEM › ANALGESICS › ANTIMIGRAINE PREPARATIONS › Calcitonin gene-related peptide (CGRP) antagonists

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Migraine143.2
Cervicogenic headache88.3
Pineal gland cyst87.5
Migraine without aura78.2
Drug ineffective71.2
Headache66.4
Product administration interrupted53.4
Therapeutic response shortened52.1
Drug effect less than expected46.1
Device difficult to use45.0
Tension headache42.4
Nausea41.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Ubrogepant is on its molecule page.

Molecular formulaC29H26F3N5O3
Molecular weight549.55 g/mol
CAS number1374248-77-7
InChIKeyDDOOFTLHJSMHLN-ZQHRPCGSSA-N
PubChem CID68748835
C[C@@H]1[C@@H](C[C@H](NC(=O)C2=CN=C3C[C@]4(CC3=C2)C(=O)NC2=NC=CC=C42)C(=O)N1CC(F)(F)F)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Ubrogepant used for?

DrugCentral lists the following indications for Ubrogepant: Migraine.

How does Ubrogepant work?

Ubrogepant is classified as Calcitonin Gene-related Peptide Receptor Antagonists; its molecular targets in DrugCentral include CALCRL (antagonist).

When was Ubrogepant first approved?

Ubrogepant was first approved by the FDA in 2019.

What drug class does Ubrogepant belong to?

Ubrogepant is in the Calcitonin Gene-related Peptide Receptor Antagonist class.

What is the chemical formula of Ubrogepant?

Ubrogepant has the molecular formula C29H26F3N5O3 and a molecular weight of 549.55 g/mol.

Browse: all drugs starting with U · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2019-12-23
AgencyFDA
Targets1
Indications1
FormulaC29H26F3N5O3
DrugCentral ID5361
Interactive profile